Theranostic and prognostic biomarkers: genomic applications in urological malignancies

References

• Stephenson AJ, Scardino PT, Eastham JA, et al Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98: 715–717.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Eastham JA, et al Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 7005–7012.
   PubMed Web of Science ®Google Scholar
• Partin AW, Kattan MW, Subong EN, et al Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445–1451.
   PubMed Web of Science ®Google Scholar
• Amin M, Boccon-Gibod L, Egevad L, et al Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl 2005; 216: 20–33.
   PubMedGoogle Scholar
• DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI, et al Pathological and molecular aspects of prostate cancer. Lancet 2003; 316: 955–964.
   Google Scholar
• De Marzo AM, DeWeese TL, Platz EA, et al Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004; 91: 459–477.
   PubMed Web of Science ®Google Scholar
• Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 366–381.
   PubMed Web of Science ®Google Scholar
• Srigley JR, Amin M, Boccon-Gibod L, et al Prognostic and predictive factors in prostate cancer: Historical perspectives and recent international consensus initiatives. Scand J Urol Nephrol Suppl 2005; 216: 8–19.
   Google Scholar
• Bethel CR, Faith D, Li X, et al Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: Association with gleason score and chromosome 8p deletion. Cancer Res 2006; 66: 10683–10690.
   PubMedGoogle Scholar
• Prowatke I, Devens F, Benner A, et al Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. Br J Cancer 2007; 96: 82–88.
   PubMed Web of Science ®Google Scholar
• Khan MA, Partin AW. Tissue microarrays in prostate cancer research. Rev Urol 2004; 6: 44–46.
   PubMedGoogle Scholar
• Tomlins SA, Rhodes DR, Perner S, et al Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644–648.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Mehra R, Rhodes DR, et al TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006; 66: 3396–3400.
   PubMed Web of Science ®Google Scholar
• Demichelis F, Fall K, Perner S, et al TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26: 4596–4599.
   PubMed Web of Science ®Google Scholar
• Lotan TL, Toubaji A, Albadine R, et al TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod Pathol 2009; 22: 359–365.
   PubMedGoogle Scholar
• Yoshimoto M, Joshua AM, Cunha IW, et al Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008; 21: 1451–1460.
   PubMed Web of Science ®Google Scholar
• FitzGerald LM, Agalliu I, Johnson K, et al Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: Results from a population-based study of prostate cancer. BMC Cancer 2008; 8: 230.
   PubMed Web of Science ®Google Scholar
• Mao X, Shaw G, James SY, et al Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian J Androl 2008; 10: 467–473.
   PubMedGoogle Scholar
• Perner S, Mosquera JM, Demichelis F, et al TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 2007; 31: 882–888.
   PubMed Web of Science ®Google Scholar
• Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008; 14: 3395–3400.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Amin M, Boccon-Gibod L, et al Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005; 216: 34–63.
   Google Scholar
• Hammond ME, Fitzgibbons PL, Compton CC, et al College of American Pathologists Conference XXXV: Solid tumor prognostic factors – which, how and so what? Summary document and recommendations for implementation. Cancer committee and conference participants. Arch Pathol Lab Med 2000; 124: 958–965.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Grignon DJ, Hammond ME, et al Prognostic factors in prostate cancer. College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 2000; 124: 995–1000.
   PubMed Web of Science ®Google Scholar
• Kremer CL, Klein RR, Mendelson J, et al Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006; 66: 1203–1212.
   PubMed Web of Science ®Google Scholar
• Sanchez D, Rosell D, Honorato B, Lopez J, Arocena J, Sanz G. Androgen receptor mutations are associated with gleason score in localized prostate cancer. BJU Int 2006; 98: 1320–1325.
   PubMed Web of Science ®Google Scholar
• Wikstrom P, Bergh A, Damber JE. Transforming growth factor-beta1 and prostate cancer. Scand J Urol Nephrol 2000; 34: 85–94.
   PubMed Web of Science ®Google Scholar
• Wikstrom P, Damber J, Bergh A. Role of transforming growth factor-beta1 in prostate cancer. Microsc Res Tech 2001; 52: 411–419.
   PubMed Web of Science ®Google Scholar
• Diaz JI, Mora LB, Austin PF, et al Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. Urology 1999; 53: 931–938.
   PubMedGoogle Scholar
• Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB–1 (ki–67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 1998; 110: 443–449.
   PubMedGoogle Scholar
• Bubendorf L, Tapia C, Gasser TC, et al Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998; 29: 949–954.
   PubMed Web of Science ®Google Scholar
• Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156: 1064–1068.
   PubMed Web of Science ®Google Scholar
• Cheng L, Pisansky TM, Sebo TJ, et al Cell proliferation in prostate cancer patients with lymph node metastasis: A marker for progression. Clin Cancer Res 1999; 5: 2820–2823.
   PubMed Web of Science ®Google Scholar
• Stapleton AM, Zbell P, Kattan MW, et al Assessment of the biologic markers p53, ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 1998; 82: 168–175.
   PubMed Web of Science ®Google Scholar
• Vis AN, van Rhijn BW, Noordzij MA, Schroder FH, van der Kwast TH. Value of tissue markers p27(kip1), MIB–1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol 2002; 197: 148–154.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Wheeler TM, Blute M, et al Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996; 48: 47–57.
   PubMed Web of Science ®Google Scholar
• Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997; 79: 772–779.
   PubMed Web of Science ®Google Scholar
• Strohmeyer D, Rossing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000; 42: 26–33.
   PubMed Web of Science ®Google Scholar
• Strohmeyer D, Strauss F, Rossing C, et al Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res 2004; 24: 1797–1804.
   PubMedGoogle Scholar
• Gettman MT, Bergstralh EJ, Blute M, Zincke H, Bostwick DG. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: Lack of significance for microvessel density analysis. Urology 1998; 51: 79–85.
   PubMed Web of Science ®Google Scholar
• Gettman MT, Pacelli A, Slezak J, et al Role of microvessel density in predicting recurrence in pathologic stage T3 prostatic adenocarcinoma. Urology 1999; 54: 479–485.
   PubMed Web of Science ®Google Scholar
• Krupski T, Petroni GR, Frierson HF Jr, Theodorescu JU. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology 2000; 55: 743–749.
   PubMed Web of Science ®Google Scholar
• Brewster SF, Oxley JD, Trivella M Abbott CD, Gillatt DA. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 1999; 161: 1238–1243.
   PubMedGoogle Scholar
• Stackhouse GB, Sesterhenn IA, Bauer JJ, et al p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999; 162: 2040–2045.
   PubMed Web of Science ®Google Scholar
• Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996; 156: 1511–1516.
   PubMed Web of Science ®Google Scholar
• Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S, Moul JW. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1995; 1: 1295–1300.
   PubMed Web of Science ®Google Scholar
• Moul JW, Bettencourt MC, Sesterhenn IA, et al Protein expression of p53, bcl-2, and KI-67 (MIB–1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996; 120: 159,166: discussion 166–7.
   PubMedGoogle Scholar
• Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression. Clin Cancer Res 1999; 5: 2082–2088.
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997; 158: 131–137.
   PubMedGoogle Scholar
• Kuczyk MA, Serth J, Bokemeyer C, et al The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer 1998; 34: 679–686.
   PubMed Web of Science ®Google Scholar
• Cheng L, Lloyd RV, Weaver AL, et al The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 2000; 6: 1896–1899.
   PubMed Web of Science ®Google Scholar
• Attard G, Swennenhuis JF, Olmos D, et al Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69: 2912–2918.
   PubMed Web of Science ®Google Scholar
• Carver BS, Tran J, Gopalan A, et al Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 619–624.
   PubMed Web of Science ®Google Scholar
• Gravina GL, Biordi L, Martella F, et al Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. Int J Oncol 2009; 35: 1133–1139.
   PubMedGoogle Scholar
• King JC, Xu J, Wongvipat J, Hieronymus H, et al Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41: 524–526.
   PubMed Web of Science ®Google Scholar
• Yoshimoto M, Cutz JC, Nuin PA, et al Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006; 169: 128–137.
   PubMedGoogle Scholar
• Schmitz M, Grignard G, Margue C, et al Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007; 120: 1284–1292.
   PubMed Web of Science ®Google Scholar
• Cao C, Subhawong T, Albert JM, et al Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006; 66: 10040–10047.
   PubMed Web of Science ®Google Scholar
• Giannakopoulos X, Stagikas D, Charalabopoulos A, Sofikitis N, Charalabopoulos K. Adjuvant and neoadjuvant therapies in high risk localized prostate cancer. J Exp Clin Cancer Res 2006; 25: 469–473.
   PubMed Web of Science ®Google Scholar
• Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65: 2825–2831.
   PubMed Web of Science ®Google Scholar
• Lacombe L, Maillette A, Meyer F, Veilleux C, Moore L, Fradet Y. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int J Cancer 2001; 95: 135–139.
   PubMed Web of Science ®Google Scholar
• Aslan G, Irer B, Tuna B, Yorukoglu K, Saatcioglu F, Celebi I. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features. Pathol Res Pract 2006; 202: 93–98.
   PubMedGoogle Scholar
• Gurel B, Iwata T, Koh CM, et al Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008; 21: 1156–1167.
   PubMed Web of Science ®Google Scholar
• Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol 2008; 15: 319–331.
   PubMedGoogle Scholar
• Veltri RW, Partin AW, Epstein JE, et al Quantitative nuclear morphometry, markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem Suppl 1994; 19: 249–258.
   PubMedGoogle Scholar
• Ross JS, Sheehan CE, Hayner-Buchan AM, et al Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997; 79: 2162–2170.
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997; 80: 2109–2119.
   PubMed Web of Science ®Google Scholar
• Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996; 27: 683–687.
   PubMed Web of Science ®Google Scholar
• McWilliam LJ, Manson C, George NJ. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 1997; 80: 287–290.
   PubMedGoogle Scholar
• Cohen RJ, Glezerson G, Haffejee Z. Neuro-endocrine cells—a new prognostic parameter in prostate cancer. Br J Urol 1991; 68: 258–262.
   PubMedGoogle Scholar
• Casella R, Bubendorf L, Sauter G, Moch H, Mihatsch MJ, Gasser TC. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol 1998; 160: 406–410.
   PubMed Web of Science ®Google Scholar
• Shariff AH, Ather MH. Neuroendocrine differentiation in prostate cancer. Urology 2006; 68: 2–8.
   PubMedGoogle Scholar
• Zhang YH, Kanamaru H, Oyama N, et al Prognostic value of nuclear morphometry on needle biopsy from patients with prostate cancer: Is volume-weighted mean nuclear volume superior to other morphometric parameters? Urology 2000; 55: 377–381.
   PubMed Web of Science ®Google Scholar
• Zhang YH, Kanamaru H, et al Comparison of nuclear morphometric results between needle biopsy and surgical specimens from patients with prostate cancer. Urology 1999; 54: 763–766.
   PubMedGoogle Scholar
• Veltri RW, Miller MC, Partin AW, Coffey DS, Epstein JI. Ability to predict biochemical progression using gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology 1996; 48: 685–691.
   PubMedGoogle Scholar
• Khan MA, Walsh PC, Miller MC, et al Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. Cancer 2003; 98: 2583–2591.
   PubMed Web of Science ®Google Scholar
• Partin AW, Steinberg GD, Pitcock RV, et al Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer 1992; 70: 161–168.
   PubMed Web of Science ®Google Scholar
• Potter SR, Miller MC, Mangold LA, et al Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 1999; 54: 791–795.
   PubMed Web of Science ®Google Scholar
• Ross JS, Sheehan CE, Fisher HA, et al Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 6357–6362.
   PubMed Web of Science ®Google Scholar
• Hammond ME, Sause WT, Martz KL, et al Correlation of prostate-specific acid phosphatase and prostate-specific antigen immunocytochemistry with survival in prostate carcinoma. Cancer 1989; 63: 461–466.
   PubMed Web of Science ®Google Scholar
• Lapointe J, Li C, Higgins JP, et al Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811–816.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Mehra R, Rhodes DR, et al Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39: 41–51.
   PubMed Web of Science ®Google Scholar
• Lapointe J, Li C, Giacomini CP, et al Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007; 67: 8504–8510.
   PubMed Web of Science ®Google Scholar
• Bastacky S, Cieply K, Sherer C, Dhir R, Epstein JI. Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy. Hum Pathol 2004; 35: 281–289.
   PubMedGoogle Scholar
• Al-Maghrabi J, Vorobyova L, Toi A, Chapman W, Zielenska M, Squire JA. Identification of numerical chromosomal changes detected by interphase fluorescence in situ hybridization in high-grade prostate intraepithelial neoplasia as a predictor of carcinoma. Arch Pathol Lab Med 2002; 126: 165–169.
   PubMedGoogle Scholar
• Dhir R, Vietmeier B, Arlotti J, et al Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004; 171: 1419–1423.
   PubMed Web of Science ®Google Scholar
• Uetsuki H, Tsunemori H, Taoka R, Haba R, Ishikawa M, Kakehi Y. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol 2005; 174: 514–518.
   PubMed Web of Science ®Google Scholar
• Hansel DE, DeMarzo AM, Platz EA, et al Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. J Urol 2007; 177: 1736–1740.
   PubMed Web of Science ®Google Scholar
• Paul B, Dhir R, Landsittel D, Hitchens MR, Getzenberg RH. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 2005; 65: 4097–4100.
   PubMedGoogle Scholar
• Bastian PJ, Ellinger J, Wellmann A, et al Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2005; 11: 4097–4106.
   PubMed Web of Science ®Google Scholar
• Bastian PJ, Nakayama M, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer. Urologe A 2004; 43: 573–579.
   PubMedGoogle Scholar
• Bastian PJ, Palapattu GS, Lin X, et al Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005; 11: 4037–4043.
   PubMed Web of Science ®Google Scholar
• Bastian PJ, Yegnasubramanian S, Palapattu GS, et al Molecular biomarker in prostate cancer: The role of CpG island hypermethylation. Eur Urol 2004; 46: 698–708.
   PubMed Web of Science ®Google Scholar
• Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975–5979.
   PubMed Web of Science ®Google Scholar
• de Kok JB, Verhaegh GW, Roelofs RW, et al DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695–2698.
   PubMed Web of Science ®Google Scholar
• Kantoff P. Recent progress in management of advanced prostate cancer. Oncology (Williston Park) 2005; 19: 631–636.
   PubMedGoogle Scholar
• Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 2001; 47: 102–110.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Carducci M. Atrasentan: A rationally designed targeted therapy for cancer. Drugs Today (Barc) 2006; 42: 299–312.
   PubMedGoogle Scholar
• Jimeno A, Carducci M. Atrasentan: A novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 2005; 5: 419–427.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res 2006; 66: 9171–9177.
   PubMed Web of Science ®Google Scholar
• Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 2006; 66: 1359–1370.
   PubMedGoogle Scholar
• Ikegami S, Yamakami K, Ono T, et al Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody. Hum Gene Ther 2006; 17: 997–1005.
   PubMedGoogle Scholar
• Jayaprakash S, Wang X, Heston WD, Kozikowski AP. Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. Chem Med Chem 2006; 1: 299–302.
   Google Scholar
• Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification. J Clin Oncol 2006; 24: 5552–5564.
   PubMed Web of Science ®Google Scholar
• Wu XR. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 2005; 5: 713–725.
   PubMed Web of Science ®Google Scholar
• Oxford G, Theodorescu D. The role of ras superfamily proteins in bladder cancer progression. J Urol 2003; 170: 1987–1993.
   PubMed Web of Science ®Google Scholar
• Kubota Y, Miyamoto H, Noguchi S, et al The loss of retinoblastoma gene in association with c-myc and transforming growth factor-beta 1 gene expression in human bladder cancer. J Urol 1995; 154: 371–374.
   PubMedGoogle Scholar
• O'Donnell MA. Advances in the management of superficial bladder cancer. Semin Oncol 2007; 34: 85–97.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, et al Predicting recurrence and progression in individual patients with stage ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466,465; discussion 475–7.
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R, et al Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666–675.
   PubMed Web of Science ®Google Scholar
• Skacel M, Fahmy M, Brainard JA, et al Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003; 169: 2101–2105.
   PubMed Web of Science ®Google Scholar
• Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 2007; 51: 1275,1280; discussion 1280.
   PubMed Web of Science ®Google Scholar
• Yoder BJ, Skacel M, Hedgepeth R, et al Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: A prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007; 127: 295–301.
   PubMed Web of Science ®Google Scholar
• Rabbani F, Koppie TM, Charytonowicz E, Drobnjak M, Bochner BH, Cordon-Cardo C. Prognostic significance of p27(Kip1) expression in bladder cancer. BJU Int 2007; 100: 259–263.
   PubMedGoogle Scholar
• Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24: 778–789.
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al Molecular profiling of bladder cancer using cDNA microarrays: Defining histogenesis and biological phenotypes. Cancer Res 2002; 62: 6973–6980.
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: Identification of molecular targets in bladder cancer. Br J Cancer 2003; 89: 2172–2177.
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M, Cordon-Cardo C. Molecular alterations associated with bladder cancer progression. Semin Oncol 2007; 34: 75–84.
   PubMed Web of Science ®Google Scholar
• Rotterud R, Nesland JM, Berner A, Fossa SD. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 2005; 95: 1344–1350.
   PubMed Web of Science ®Google Scholar
• Lascombe I, Clairotte A, Fauconnet S, et al N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res 2006; 12: 2780–2787.
   PubMed Web of Science ®Google Scholar
• Ioachim E, Michael MC, Salmas M, et al Thrombospondin-1 expression in urothelial carcinoma: Prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer 2006; 6: 140.
   PubMed Web of Science ®Google Scholar
• Highshaw RA, McConkey DJ, Dinney CP. Integrating basic science and clinical research in bladder cancer: Update from the first bladder specialized program of research excellence (SPORE). Curr Opin Urol 2004; 14: 295–300.
   PubMedGoogle Scholar
• Clairotte A, Lascombe I, Fauconnet S, et al Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: Identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol 2006; 125: 119–126.
   PubMed Web of Science ®Google Scholar
• Chatterjee SJ, Datar R, Youssefzadeh D, et al Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22: 1007–13
   PubMed Web of Science ®Google Scholar
• Beekman KW, Bradley D, Hussain M. New molecular targets and novel agents in the treatment of advanced urothelial cancer. Semin Oncol 2007; 34: 154–164.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007; 177: 481–487; discussion 487.
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Kubota Y, Fujinami K, et al Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: P16 mutations occur only in low-grade and superficial bladder cancers. Oncol Res 1995; 7: 327–330.
   PubMedGoogle Scholar
• Miyamoto H, Kubota Y, Shuin T, et al Analyses of p53 gene mutations in primary human bladder cancer. Oncol Res 1993; 5: 245–249.
   PubMedGoogle Scholar
• Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 1995; 71: 831–835.
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Dalbagni G, Cordon-Cardo C, et al Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 1993; 85: 53–59.
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Dalbagni G, Cordon-Cardo C, et al Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994; 152: 388–392.
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Bajorin DF, Reuter VE, et al Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13: 1384–1390.
   PubMed Web of Science ®Google Scholar
• Garcia del Muro X, Condom E, Vigues F, et al p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004; 100: 1859–1867.
   PubMedGoogle Scholar
• Tzai TS, Tsai YS, Chow NH. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. Urol Oncol 2004; 22: 112–118.
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Presti JC Jr, Reuter VE, et al Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 1993; 2: 4–13.
   PubMed Web of Science ®Google Scholar
• Margulis V, Lotan Y, Karakiewicz PI, et al Multi-institutional validation of the predictive value of ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009; 101: 114–119.
   PubMedGoogle Scholar
• Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003; 46 (Suppl): S85–S104.
   Google Scholar
• Black PC, Agarwal PK, Dinney CP. Targeted therapies in bladder cancer—an update. Urol Oncol 2007; 25: 433–438.
   PubMed Web of Science ®Google Scholar
• Black PC, Dinney CP. Bladder cancer angiogenesis and metastasis—translation from murine model to clinical trial. Cancer Metastasis Rev 2007; 26: 623–634.
   PubMed Web of Science ®Google Scholar
• Wallerand H, Reiter RR, Ravaud A. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways. Curr Opin Urol 2008; 18: 524–532.
   PubMedGoogle Scholar
• Wallerand H, Robert G, Bernhard JC, Ravaud A, Ferriere JM. Targeted therapy for locally advanced and/or metastatic bladder cancer. Prog Urol 2008; 18: 407–417.
   PubMedGoogle Scholar
• Amin MB, Amin MB, Tamboli P, et al Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol 2002; 26: 281–291.
   PubMed Web of Science ®Google Scholar
• Patard JJ, Leray E, Rioux-Leclercq N, et al Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol 2005; 23: 2763–2771.
   PubMed Web of Science ®Google Scholar
• Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27: 612–624.
   PubMed Web of Science ®Google Scholar
• Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am 2008; 35: 613–625; vii.
   PubMed Web of Science ®Google Scholar
• Kim HL, Seligson D, Liu X, et al Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005; 173: 1496–1501.
   PubMed Web of Science ®Google Scholar
• Kim HL, Seligson D, Liu X, et al Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004; 10: 5464–5471.
   PubMed Web of Science ®Google Scholar
• Kluger HM, Siddiqui SF, Angeletti C, et al Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest 2008; 88: 962–972.
   PubMed Web of Science ®Google Scholar
• Hager M, Haufe H, Kemmerling R, et al Increased activated akt expression in renal cell carcinomas and prognosis. J Cell Mol Med 2009; 13 (8B): 2181–2188.
   PubMedGoogle Scholar
• Eichelberg C, Junker K, Ljungberg B, Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: A critical appraisal of the current state of research and clinical applicability. Eur Urol 2009; 55: 851–863.
   PubMed Web of Science ®Google Scholar
• Djordjevic G, Mozetic V, Mozetic DV, et al Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol Res Pract 2007; 203: 99–106.
   PubMed Web of Science ®Google Scholar
• Bensalah K, Pantuck AJ, Crepel M, et al Prognostic variables to predict cancer-related death in incidental renal tumours. BJU Int 2008; 102: 1376–1380.
   PubMedGoogle Scholar
• Pantuck AJ, Seligson DB, Klatte T, et al Prognostic relevance of the mTOR pathway in renal cell carcinoma: Implications for molecular patient selection for targeted therapy. Cancer 2007; 109: 2257–2267.
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Thomas G, Belldegrun AS, Figlin RA. Mammalian target of rapamycin inhibitors in renal cell carcinoma: Current status and future applications. Semin Oncol 2006; 33: 607–613.
   PubMedGoogle Scholar
• Bui MH, Seligson D, Han KR, et al Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802–811.
   PubMed Web of Science ®Google Scholar
• Atkins M, Regan M, McDermott D, et al Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 3714–3721.
   PubMed Web of Science ®Google Scholar
• Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004; 93: 297–302.
   PubMed Web of Science ®Google Scholar
• Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005; 11: 1129–1135.
   PubMed Web of Science ®Google Scholar
• Migita T, Oda Y, Naito S, Tsuneyoshi M. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 2002; 94: 973–979.
   PubMed Web of Science ®Google Scholar
• Hedberg Y, Davoodi E, Ljungberg B, Roos G, Landberg G. Cyclin E and p27 protein content in human renal cell carcinoma: Clinical outcome and associations with cyclin D. Int J Cancer 2002; 102: 601–607.
   PubMedGoogle Scholar
• Hedberg Y, Ljungberg B, Roos G, Landberg G. Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer 2003; 88: 1417–1423.
   PubMed Web of Science ®Google Scholar
• Linehan WM, Pinto PA, Srinivasan R, et al Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007; 13: 671–679s.
   PubMed Web of Science ®Google Scholar
• Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991–5004.
   PubMed Web of Science ®Google Scholar
• Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477–2490.
   PubMed Web of Science ®Google Scholar
• Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996; 93: 10595–10599.
   PubMed Web of Science ®Google Scholar
• Kroog GS, Motzer RJ. Systemic therapy for metastatic renal cell carcinoma. Urol Clin North Am 2008; 35: 687–701; ix.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bukowski RM, Figlin RA, et al Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008; 113: 1552–1558.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Thompson JA. Temsirolimus in patients with advanced renal cell carcinoma: An overview. Adv Ther 2009; 26: 55–67.
   PubMedGoogle Scholar
• Patard JJ, Pouessel D, Bensalah K, Culine S. Targeted therapy in renal cell carcinoma. World J Urol 2008; 26: 135–140.
   PubMedGoogle Scholar
• Patard JJ, Pouessel D, Culine S. New therapies in renal cell carcinoma. Curr Opin Support Palliat Care 2007; 1: 174–179.
   PubMedGoogle Scholar
• Patard JJ, Thuret R, Raffi A, Laguerre B, Bensalah K, Culine S. Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol 2009; 55: 237–239.
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, et al A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–434.
   PubMed Web of Science ®Google Scholar
• Steffens MG, Boerman OC, de Mulder PH, et al Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999; 5: 3268–3274s.
   Web of Science ®Google Scholar